A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

Authors:

Abstract
TPS6090Background: Although the EXTREME regimen is a Category 1 evidence-supported combination recommended by NCCN guidelines as first-line (1L) treatment for patients with R/M SCCHN, it is associated with limited survival benefit and burdensome toxicities. There remains a high unmet need for more effective and well tolerated treatment strategies. Both the programmed cell death 1 (PD-1) receptor and indoleamine 2,3-dioxygenase 1 (IDO1) enzyme have been identified as key mechanisms that suppress T-cell–mediated antitumor immunity and induce tumor escape. Pembrolizumab (P) is a potent, highly selective humanized monoclonal antibody that directly blocks the interaction of PD-1 and its ligands. Epacadostat (E) is a potent, highly selective oral inhibitor of IDO1. Preliminary phase 1/2 data from the ECHO-202/KEYNOTE-037 study showed encouraging efficacy results and a tolerable safety profile with E + P in SCCHN. This randomized, open-label, phase 3 global study (NCT03358472) evaluates the efficacy and safety o...